Compare · BAX vs PROF
BAX vs PROF
Side-by-side comparison of Baxter International Inc. (BAX) and Profound Medical Corp. (PROF): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BAX and PROF operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BAX is the larger of the two at $9.35B, about 44.3x PROF ($211.3M).
- Over the past year, BAX is down 40.5% and PROF is up 48.4% - PROF leads by 89.0 points.
- BAX has been more active in the news (5 items in the past 4 weeks vs 4 for PROF).
- BAX has more recent analyst coverage (25 ratings vs 7 for PROF).
- Company
- Baxter International Inc.
- Profound Medical Corp.
- Price
- $18.15-1.44%
- $7.05+4.60%
- Market cap
- $9.35B
- $211.3M
- 1M return
- +5.95%
- +20.72%
- 1Y return
- -40.53%
- +48.42%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 5
- 4
- Recent ratings
- 25
- 7
Baxter International Inc.
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.
Profound Medical Corp.
Profound Medical Corp., together with its subsidiaries, operates as a medical technology company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
Latest BAX
- Baxter Showcases Recent Innovations at AORN Global Surgical Conference & Expo 2026
- SEC Form 3 filed by new insider Foster Julie
- SEC Form 3 filed by new insider Wallace Steven P.
- SEC Form 3 filed by new insider Teaff James
- Baxter to Host First-Quarter 2026 Financial Results Conference Call for Investors
- Baxter Introduces the IV Verify Line Labeling System, an Automated Solution to Improve IV Labeling in Healthcare Settings
- Baxter to Host Annual Meeting of Stockholders in Virtual Format
- Pet Partners and the Baxter Foundation Expand Therapy Animal Programs to Support 100,000 Patients and Healthcare Workers in Two-Year Pilot
- SEC Form DEFA14A filed by Baxter International Inc.
- SEC Form DEF 14A filed by Baxter International Inc.
Latest PROF
- Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Profound Medical to Release First Quarter 2026 Financial Results on May 7 – Conference Call to Follow
- Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
- Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone
- Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- CAPTAIN Trial Comparing Profound's MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence
- Profound Medical Corp. filed SEC Form 8-K: Leadership Update